| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.35 | 9e-11 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.33 | 4e-10 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-09 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.25 | 5e-09 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.24 | 2e-08 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.23 | 2e-08 |
| mRNA | lovastatin | CTRPv2 | pan-cancer | AAC | -0.24 | 5e-08 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | -0.23 | 1e-07 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.22 | 2e-07 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.28 | 6e-06 |